Full Generic Medicine Info
Dosage/Direction for Use

Vitamin D-resistant rickets (familial hypophosphataemia)
Adult: Dosage is individualised according to patient response and requirement. 12,000-500,000 IU daily. Alternatively, 10,000-60,000 IU daily may be given with phosphate supplements. Readjust dose as soon as clinical improvement is observed. Frequent serum Ca determination is recommended when high therapeutic doses are used.

Adult: Dosage is individualised according to patient response and requirement. In combination with Ca supplements and/or IV parathyroid hormone or dihydrotachysterol: 50,000-200,000 IU daily. Readjust dose as soon as clinical improvement is observed.
Child: Same as adult dose.

Vitamin D deficiency
Adult: Dosage is individualised according to patient response and requirement. Prophylaxis: 400 IU daily. Treatment: 800 IU daily, may require higher doses in severe deficiency. Alternatively, 50,000 IU once weekly may be necessary. In patients with deficiency due to liver disease or malabsorption states: Up to 40,000 IU daily.
Hypercalcaemia, metastatic calcification, evidence of vitamin D toxicity, hypervitaminosis D, abnormal sensitivity to toxic effects of vitamin D; malabsorption syndrome (unless dosed appropriately).
Special Precautions
Patient with heart disease or arteriosclerosis, renal calculi, hyperphosphataemia. Obese patients (BMI >30 kg/m2). Treatment guidelines may vary among individual products (refer to product-specific recommendations). Renal impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor serum or urinary Ca and phosphorus concentrations, and BUN initially once or twice weekly then at regular intervals; renal function as clinically indicated. Perform bone X-ray every month until the condition is stabilised and corrected. Monitor for signs and symptoms of vitamin D toxicity.
Adverse Reactions
Significant: Hypercalcaemia, soft tissue calcification, hypercalciuria, vitamin D toxicity. Gastrointestinal disorders: Nausea, abdominal pain, vomiting, constipation. General disorders and administration site conditions: Weakness. Investigations: Increased serum creatinine, weight loss. Metabolism and nutrition disorders: Anorexia, thirst. Nervous system disorders: Headache. Renal and urinary disorders: Polyuria, nocturia.
Symptoms: Hypercalcaemia with anorexia, nausea, vomiting, constipation, diarrhoea, polyuria, nocturia, thirst, lassitude, headache, sweating, and vertigo. Management: Symptomatic and supportive treatment. In case of hypercalcaemia, discontinue treatment and initiate low Ca diet or generous fluid intake. May require hydration with IV saline solution in severe cases.
Drug Interactions
Mineral oil and colestyramine may interfere with the absorption of vitamin D. May cause hypercalcaemia with thiazide diuretics in hypoparathyroid patients. May reduce the efficacy with rifampicin and isoniazid. Metabolism may be increased by phenytoin. May increase the arrhythmogenic effects of cardiac glycosides.
Ergocalciferol is a provitamin. Its active metabolite stimulates the Ca and phosphorous absorption by the small intestine, increases secretion of Ca from bone to blood, and promotes renal tubule phosphate reabsorption. Synonym: calciferol, vitamin D2.
Onset: 10-24 hours. Max effect: Approx 1 month (after daily doses).
Absorption: Well absorbed from the small intestine.
Distribution: Crosses the placenta and enters breast milk. Distributed in fat, muscle, skin and bones.
Metabolism: Metabolised in the liver by vitamin D 25-hydroxylase via hydroxylation to form 25-hydroxyergocalciferol; further metabolised in the kidneys by vitamin D 1-hydroxylase to active 1,25-dihydroxyergocalciferol.
Excretion: Via faeces; urine (small amounts).
Oral: Store between 15-30°C. Protect from light.
ATC Classification
A11CC01 - ergocalciferol ; Belongs to the class of vitamin D and analogues. Used as dietary supplements.
Disclaimer: This information is independently developed by CIMS based on ergocalciferol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in